Literature DB >> 29241739

BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin.

Jau-Yu Liau1, Jia-Huei Tsai2, Wen-Chang Huang3, Jui Lan4, Jin-Bon Hong5, Chang-Tsu Yuan6.   

Abstract

Tubular apocrine adenoma (TAA) and papillary eccrine adenoma (PEA) are benign sweat gland tumors. Their names imply that they exhibit apocrine and eccrine differentiation, respectively. However, morphologically they are very similar and are often indistinguishable. The molecular pathogenesis of either tumor is poorly understood at present. On the basis of an index case of nipple adenoma that was morphologically reminiscent of cutaneous TAA/PEA and harbored a BRAFV600E mutation, we investigated whether a similar genetic change is also present in TAA/PEA. BRAF, RAS, and PIK3CA mutation analyses, and BRAFV600E-specific immunohistochemistry were performed for 24 TAAs/PEAs, 10 eccrine poromas, 7 apocrine cystadenomas, 2 TAA-like adenomas associated with nevus sebaceus, and one apocrine adenoma probably arising in anogenital mammary-like glands (AGMLGs). The results demonstrated that BRAFV600E mutations were present in TAAs (9/15, 60%) and PEAs (7/9, 78%), but not in other neoplasms. Two additional TAAs harbored KRASG12D mutations. In addition, a KRASG12C mutation was identified in one nevus sebaceus-associated TAA-like adenoma. The speculated AGMLG-related apocrine adenoma had a PIK3CAH1047R mutation. We concluded that activating BRAF and KRAS mutations were commonly present in TAAs/PEAs, indicating that in addition to a morphological resemblance, they are closely related genetically. Therefore, they could be considered to be united as a single entity. By contrast, the apocrine adenoma probably arising in AGMLG harbored a PIK3CA mutation, which is also commonly present in hidradenoma papilliferum. Further studies are necessary to determine whether the pathogenesis of AGMLG-related tumors is similar to breast tumors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; Papillary eccrine adenoma; RAS; Syringocystadenoma papilliferum; Tubular apocrine adenoma

Mesh:

Substances:

Year:  2017        PMID: 29241739     DOI: 10.1016/j.humpath.2017.12.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  microRNA Let-7b: A Novel treatment for endometriosis.

Authors:  Cagdas Sahin; Ramanaiah Mamillapalli; Kyong W Yi; Hugh S Taylor
Journal:  J Cell Mol Med       Date:  2018-07-31       Impact factor: 5.310

2.  Tubular apocrine adenoma of the eyelid - A case report and literature review.

Authors:  Maya Eiger-Moscovich; Paul J L Zhang; Sara E Lally; Carol L Shields; Ralph C Eagle; Tatyana Milman
Journal:  Saudi J Ophthalmol       Date:  2019-07-26

Review 3.  Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors.

Authors:  Nicolas Macagno; Pierre Sohier; Thibault Kervarrec; Daniel Pissaloux; Marie-Laure Jullie; Bernard Cribier; Maxime Battistella
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

Review 4.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.